For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Tafamidis and the formulated version represents a true advancement . These novel therapies protect the transthyretin protein, preventing its harmful build-up and reducing the severity of the condition . Patients are now experiencing